Generic Name: cabotegravir

Pronunciation: N/A

Abbreviation: CAB LA

Other Market Name: N/A

Drug Class: Integrase Inhibitors

Company: ViiV Healthcare

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cabotegravir has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

General Info

Cabotegravir is an experimental long-acting injectable HIV medication. It contains one integrase inhibitor. It is currently in Phase III clinical trials for the prevention of HIV as pre-exposure prophylaxis (PrEP).


Dosing Info:

This is a long-acting injectable HIV medication administered every eight weeks.

Side Effects


Other Info

Last Reviewed: September 25, 2018